Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

Hospira UK Ltd
Queensway, Royal Leamington Spa, Warwickshire, CV31 3RW
Telephone: +44 (0)1926 820 820
Fax: +44 (0) 1926 834446
WWW: http://www.hospira.com
Medical Information Direct Line: +44 (0) 1926 834400
Medical Information e-mail: medinfouk@hospira.com
Customer Care direct line: +44 (0)1926 821 022

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 02/06/2009
SPC Vinblastine Sulphate 1 mg/ml Injection

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/06/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   01-Jan-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company




7.         MARKETING AUTHORISATION HOLDER

 Address change

          Hospira UK Limited

Queensway

Royal Leamington Spa

Warwickshire, CV31 3RW

UK

9.         DATE OF RENEWAL OF AUTHORISATION

 

 Date change
25th September 2003

 

 

10.       DATE OF (PARTIAL) REVISION OF THE TEXT

 

            January 2008 (V1404-6-7)

 
Updated on 16/01/2004 and displayed until 02/06/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 05/01/2004 and displayed until 16/01/2004
Reasons for adding or updating:
  • Change to section 4.2 - Posology and Method of Administration
  • Change to section 4.4 - Special Warnings and Precautions for Use
  • Change to section 4.8 - Undesirable Effects
  • Pending
Updated on 20/08/2001 and displayed until 05/01/2004
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 16/08/2001 and displayed until 20/08/2001
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
  vinblastine sulfate